Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 299

1.

Synthesis of new carboxylesterase inhibitors and evaluation of potency and water solubility.

Wheelock CE, Severson TF, Hammock BD.

Chem Res Toxicol. 2001 Dec;14(12):1563-72.

PMID:
11743738
2.

Use of ab initio calculations to predict the biological potency of carboxylesterase inhibitors.

Wheelock CE, Colvin ME, Uemura I, Olmstead MM, Sanborn JR, Nakagawa Y, Jones AD, Hammock BD.

J Med Chem. 2002 Dec 5;45(25):5576-93.

PMID:
12459025
3.

Structure-activity relationships for substrates and inhibitors of mammalian liver microsomal carboxylesterases.

Huang TL, Shiotsuki T, Uematsu T, Borhan B, Li QX, Hammock BD.

Pharm Res. 1996 Oct;13(10):1495-500.

PMID:
8899840
4.

Use of classical and 3-D QSAR to examine the hydration state of juvenile hormone esterase inhibitors.

Wheelock CE, Nakagawa Y, Akamatsu M, Hammock BD.

Bioorg Med Chem. 2003 Nov 17;11(23):5101-16.

PMID:
14604674
5.

Substituted trifluoroketones as potent, selective inhibitors of mammalian carboxylesterases.

Ashour MB, Hammock BD.

Biochem Pharmacol. 1987 Jun 15;36(12):1869-79.

PMID:
3593399
6.

Comparison of benzil and trifluoromethyl ketone (TFK)-mediated carboxylesterase inhibition using classical and 3D-quantitative structure-activity relationship analysis.

Harada T, Nakagawa Y, Wadkins RM, Potter PM, Wheelock CE.

Bioorg Med Chem. 2009 Jan 1;17(1):149-64. doi: 10.1016/j.bmc.2008.11.008. Epub 2008 Nov 9.

7.

Applications of carboxylesterase activity in environmental monitoring and toxicity identification evaluations (TIEs).

Wheelock CE, Phillips BM, Anderson BS, Miller JL, Miller MJ, Hammock BD.

Rev Environ Contam Toxicol. 2008;195:117-78. Review.

PMID:
18418956
8.

Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application.

Yoon KJ, Hyatt JL, Morton CL, Lee RE, Potter PM, Danks MK.

Mol Cancer Ther. 2004 Aug;3(8):903-9.

9.

Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hydrolase (FAAH).

Wheelock CE, Nishi K, Ying A, Jones PD, Colvin ME, Olmstead MM, Hammock BD.

Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. Epub 2007 Nov 26.

10.

Acyl-coenzyme A:cholesterol O-acyltransferase is not identical to liver microsomal carboxylesterase.

Diczfalusy MA, Björkhem I, Einarsson K, Alexson SE.

Arterioscler Thromb Vasc Biol. 1996 Apr;16(4):606-10.

11.

Different inhibitory effects in rat and human carboxylesterases.

Takahashi S, Katoh M, Saitoh T, Nakajima M, Yokoi T.

Drug Metab Dispos. 2009 May;37(5):956-61. doi: 10.1124/dmd.108.024331. Epub 2009 Feb 18.

12.
13.

Evaluation of alpha-cyanoesters as fluorescent substrates for examining interindividual variation in general and pyrethroid-selective esterases in human liver microsomes.

Wheelock CE, Wheelock AM, Zhang R, Stok JE, Morisseau C, Le Valley SE, Green CE, Hammock BD.

Anal Biochem. 2003 Apr 15;315(2):208-22.

PMID:
12689831
14.

Heterocyclic derivatives of 3-substituted-1,1,1-trifluoro-2-propanones as inhibitors of esterolytic enzymes.

Székács A, Halarnkar PP, Olmstead MM, Prag KA, Hammock BD.

Chem Res Toxicol. 1990 Jul-Aug;3(4):325-32.

PMID:
2133080
15.

Identification and characterization of hepatic carboxylesterases hydrolyzing hydrocortisone esters.

Ali B, Kaur S, James EC, Parmar SS.

Biochem Pharmacol. 1985 Jun 1;34(11):1881-6.

PMID:
4004904
16.

Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity.

Hyatt JL, Tsurkan L, Wierdl M, Edwards CC, Danks MK, Potter PM.

Mol Cancer Ther. 2006 Sep;5(9):2281-8.

17.

Analysis of mammalian carboxylesterase inhibition by trifluoromethylketone-containing compounds.

Wadkins RM, Hyatt JL, Edwards CC, Tsurkan L, Redinbo MR, Wheelock CE, Jones PD, Hammock BD, Potter PM.

Mol Pharmacol. 2007 Mar;71(3):713-23. Epub 2006 Dec 13.

18.

Characterization of neuropathy target esterase using trifluoromethyl ketones.

Thomas TC, Székács A, Rojas S, Hammock BD, Wilson BW, McNamee MG.

Biochem Pharmacol. 1990 Dec 15;40(12):2587-96.

PMID:
2260984
19.

Structural requirements for the inhibition of human monocyte carboxylesterase by organophosphorus compounds.

Saboori AM, Lang DM, Newcombe DS.

Chem Biol Interact. 1991;80(3):327-38.

PMID:
1954660
20.

Isolation and pharmacological characterization of microsomal human liver flumazenil carboxylesterase.

Kleingeist B, Böcker R, Geisslinger G, Brugger R.

J Pharm Pharm Sci. 1998 Jan-Apr;1(1):38-46.

Items per page

Supplemental Content

Write to the Help Desk